Functional proteogenomics reveals biomarkers and therapeutic targets in lymphomas

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 25, 2017, Pages 6581-6586

  Rolland, Delphine C M ^a   Basrur, Venkatesha ^b   Jeon, Yoon Kyung ^c   McNeil Schwalm, Carla ^b   Fermin, Damian ^b   Conlon, Kevin P ^b   Zhou, Yeqiao ^a   Ng, Samuel Y ^d   Tsou, Chih Chiang ^b   Brown, Noah A ^b   Thomas, Dafydd G ^b   Bailey, Nathanael G ^b   Omenn, Gilbert S ^b   Nesvizhskii, Alexey I ^b   Root, David E ^d   Weinstock, David M ^d   Faryabi, Robert B ^a   Lim, Megan S ^a   Elenitoba Johnson, Kojo S J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c Seoul National University Hospital   (South Korea)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Biomarkers; CRISPR screen; Lymphoma; Proteomics; RNA seq

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ARYLDIALKYLPHOSPHATASE 2; CD19 ANTIGEN; CD2 ANTIGEN; CD22 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CD79A ANTIGEN; CD79B ANTIGEN; CYTOKINE RECEPTOR; GLYCOPROTEIN; GUIDE RNA; HERMES ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 31 RECEPTOR BETA; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 2; N GLYCOPROTEIN; NUCLEOPHOSMIN; ONCOSTATIN M; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT5B PROTEIN; TRANSCRIPTOME; TUMOR MARKER; UNCLASSIFIED DRUG; PROTEIN TYROSINE KINASE;

ANAPLASTIC LARGE CELL LYMPHOMA; ANAPLASTIC LYMPHOMA KINASE POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CARCINOGENESIS; CELL ADHESION; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; DIFFUSE LARGE B CELL LYMPHOMA; DOWN REGULATION; FUNCTIONAL GENOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; LYSOSOME MEMBRANE; MASS SPECTROMETRY; MOUSE; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN MOTIF; PROTEOGENOMICS; PROTEOMICS; RNA SEQUENCE; SIGNAL TRANSDUCTION; SOLID PHASE EXTRACTION; TRANSCRIPTOMICS; UPREGULATION; GENETICS; LYMPHOMA; PROCEDURES; TUMOR CELL LINE;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; HUMANS; LYMPHOMA; PROTEOGENOMICS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 85021116647     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1701263114     Document Type: Article

References (35)

1. Pan S, Chen R, Aebersold R, Brentnall TA (2011) Mass spectrometry based glycoproteomics-from a proteomics perspective. Mol Cell Proteomics 10:R110. 003251.
2. Zhang H, Li XJ, Martin DB, Aebersold R (2003) Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 21:660-666.
3. Roth J (2002) Protein N-glycosylation along the secretory pathway: Relationship to organelle topography and function, protein quality control, and cell interactions. Chem Rev 102:285-303.
4. Ramos-Medina R, et al. (2011) Immunohistochemical analysis of HLDA9 Workshop antibodies against cell-surface molecules in reactive and neoplastic lymphoid tissues. Immunol Lett 134:150-156.
5. Oflazoglu E, Kissler KM, Sievers EL, Grewal IS, Gerber HP (2008) Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 142:69-73.
6. Reff ME, et al. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445.
7. Smith MR (2003) Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance. Oncogene 22:7359-7368.
8. Porter DL, Kalos M, Zheng Z, Levine B, June C (2011) Chimeric antigen receptor therapy for B-cell malignancies. J Cancer 2:331-332.
9. Wang T, et al. (2015) Identification and characterization of essential genes in the human genome. Science 350:1096-1101.
10. Zhou Y, Aebersold R, Zhang H (2007) Isolation of N-linked glycopeptides from plasma. Anal Chem 79:5826-5837.
11. Fermin D, Basrur V, Yocum AK, Nesvizhskii AI (2011) Abacus: A computational tool for extracting and pre-processing spectral count data for label-free quantitative proteomic analysis. Proteomics 11:1340-1345.
12. Vizcaíno JA, et al. (2013) The PRoteomics IDEntifications (PRIDE) database and associated tools: Status in 2013. Nucleic Acids Res 41:D1063-D1069.
13. Hirokawa T, Boon-Chieng S, Mitaku S (1998) SOSUI: Classification and secondary structure prediction system for membrane proteins. Bioinformatics 14:378-379.
14. Schwartz D, Gygi SP (2005) An iterative statistical approach to the identification of protein phosphorylationmotifs from large-scale data sets. Nat Biotechnol 23:1391-1398.
15. Swerdlow SHCE, et al. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed Vardiman JW (IARC Press, Lyon, France), 4th Ed, Vol 2.
16. Picker LJ, Weiss LM, Medeiros LJ, Wood GS, Warnke RA (1987) Immunophenotypic criteria for the diagnosis of non-Hodgkin's lymphoma. Am J Pathol 128:181-201.
17. Fernàndez V, et al. (2010) Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 70:1408-1418.
18. Shaw AT, et al. (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394.
19. Barrett T, et al. (2013) NCBI GEO: Archive for functional genomics data sets-update. Nucleic Acids Res 41:D991-D995.
20. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550.
21. Zhang B, et al.; NCI CPTAC (2014) Proteogenomic characterization of human colon and rectal cancer. Nature 513:382-387.
22. Auguste P, et al. (1997) Signaling of type II oncostatin M receptor. J Biol Chem 272: 15760-15764.
23. Chiarle R, et al. (2005) Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 11:623-629.
24. Tanaka M, Miyajima A (2003) Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 149:39-52.
25. Pedrioli PG (2010) Trans-proteomic pipeline: A pipeline for proteomic analysis. Methods Mol Biol 604:213-238.
26. Keller A, Nesvizhskii AI, Kolker E, Aebersold R (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 74:5383-5392.
27. Nesvizhskii AI, Keller A, Kolker E, Aebersold R (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 75:4646-4658.
28. Paoletti AC, et al. (2006) Quantitative proteomic analysis of distinct mammalian Mediator complexes using normalized spectral abundance factors. Proc Natl Acad Sci USA 103:18928-18933.
29. R Core Team (2014) R: A Language and Environment for Statistical Computing (F Foundation for Statistical Reporting, Vienna). Available at www.R-project.org/. Accessed February 8, 2016.
30. Dobin A, et al. (2013) STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29:15-21.
31. Szklarczyk D, et al. (2015) STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43:D447-D452.
32. Shannon P, et al. (2003) Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 13:2498-2504.
33. Shao DD, et al. (2013) ATARiS: Computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res 23:665-678.
34. Liberzon A, et al. (2015) The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst 1:417-425.
35. Eyre TA, et al. (2006) The HUGO Gene Nomenclature Database, 2006 updates. Nucleic Acids Res 34:D319-D321.